Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4140
Title: Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance
Authors: Mitchell, R.
Hennig, S.
Lawson, R.
Staatz, C. E.
Fraser, C. J.
Ramachandran, S.
Teague, L.
O'Brien, T.
Issue Date: 2022
Source: , 2022
Journal: CPT: Pharmacometrics and Systems Pharmacology
Abstract: This study aimed to characterize the population pharmacokinetics (PK) of busulfan focusing on how busulfan clearance (CL) changes over time during once-daily administration and assess different methods for measuring busulfan exposure and the ability to achieve target cumulative exposure under different dosing adjustment scenarios in pediatric stem cell transplantation recipients. Daily serial blood sampling was performed and concentration-time data were analyzed using a nonlinear mixed-effects approach. The developed PK model was used to assess achievement of target exposure under six dose-adjustment scenarios based on simulations performed in RStudio (RxODE package)®. A total of 2491 busulfan plasma concentration–time measurements were collected from 95 patients characterizing 379 dosing days. A two-compartment model with time-associated CL best described the data with a typical CL of 14.5 L/h for an adult male with 62 kg normal fat mass (NFM; equivalent to 70 kg total body weight), typical volume of distribution central compartment (V1) of 40.6 L/59 kg NFM (equivalent to 70 kg total body weight), and typical volume of distribution peripheral compartment of 3.57 L/62 kg NFM. Model interindividual variability in CL and V1 was 14.7% and 34.9%, respectively, and interoccasional variability in CL was 6.6%. Patient size described by NFM, a maturation component, and time since start of treatment significantly influenced CL. Simulations demonstrated that using model-based exposure estimates with each dose, and either a proportional dose-adjustment calculation or model-based calculated individual CL estimates to support dose adjustments, increased proportion of subjects attaining cumulative exposure within 5% of target compared with using noncompartmental analysis (100% vs. 0%). A time-associated reduction in CL during once-daily busulfan treatment was described.L20179255642022-06-21
DOI: 10.1002/psp4.12809
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L2017925564&from=exporthttp://dx.doi.org/10.1002/psp4.12809 |
Keywords: simulation;achievementadult;article;blood sampling;body weight;calculation;child;compartment model;controlled study;drug therapy;fat mass;human;human tissue;intravenous drug administration;major clinical study;male;pharmacokinetics;stem cell transplantation;volume of distribution;busulfan
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

56
checked on Feb 14, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.